Calidi Biotherapeutics Presents New Data on Therapeutic Lead CLD-401 at SITC Annual Meeting and Holds First Investor Day

Calidi Biotherapeutics presented new data on its therapeutic lead, CLD-401, at the 2025 SITC Annual Meeting. CLD-401 is a tumor-tropic oncolytic virus designed to home to metastatic sites after systemic administration and induce an immune priming event at the tumor site. The data demonstrate that the RedTail platform is protected from immune clearance and can express genetic medicines at the tumor site in concentrations similar to localized dosing. Calidi is conducting IND-enabling studies for CLD-401 and anticipates submitting an IND application by the end of 2026.